stoxline Quote Chart Rank Option Currency Glossary
Mersana Therapeutics, Inc. (MRSN)
2.38  0 (0%)    05-28 15:33
Open: 2.38
High: 2.42
Volume: 941,790
Pre. Close: 2.38
Low: 2.27
Market Cap: 291(M)
Technical analysis
2024-05-28 3:23:22 PM
Short term     
Mid term     
Targets 6-month :  3.63 1-year :  4.23
Resists First :  3.11 Second :  3.63
Pivot price 2.69
Supports First :  2.26 Second :  1.88
MAs MA(5) :  2.48 MA(20) :  2.86
MA(100) :  3.72 MA(250) :  2.91
MACD MACD :  -0.4 Signal :  -0.4
%K %D K(14,3) :  5.6 D(3) :  7.5
RSI RSI(14): 30.9
52-week High :  9.61 Low :  0.8
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MRSN ] has closed above bottom band by 25.7%. Bollinger Bands are 16.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.51 - 2.53 2.53 - 2.54
Low: 2.33 - 2.35 2.35 - 2.37
Close: 2.35 - 2.38 2.38 - 2.4
Company Description

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 22 May 2024
Mersana Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance

Wed, 15 May 2024
Mersana: On Hold While Waiting For Any Positive News (NASDAQ:MRSN) - Seeking Alpha

Tue, 14 May 2024
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Thu, 09 May 2024
Mersana Therapeutics Updates Corporate Presentation Online - TipRanks

Thu, 09 May 2024
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Thu, 09 May 2024
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 122 (M)
Shares Float 65 (M)
Held by Insiders 1.3 (%)
Held by Institutions 94.8 (%)
Shares Short 10,580 (K)
Shares Short P.Month 8,730 (K)
Stock Financials
EPS -1.49
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.31
Profit Margin 0 %
Operating Margin -195.6 %
Return on Assets (ttm) -38.2 %
Return on Equity (ttm) -266.3 %
Qtrly Rev. Growth -27.2 %
Gross Profit (p.s.) 0
Sales Per Share 0.3
EBITDA (p.s.) -1.39
Qtrly Earnings Growth 0 %
Operating Cash Flow -169 (M)
Levered Free Cash Flow -86 (M)
Stock Valuations
PE Ratio -1.61
PEG Ratio 0
Price to Book value 7.67
Price to Sales 7.9
Price to Cash Flow -1.73
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android